

lethargy, diarrhea, weight loss, and/or vomiting. Peripheral lymphadenopathy was not clinically evident in any of the cats. The most frequent clinicopathologic abnormalities were thrombocytopenia and anemia, although directional abnormalities in leukocyte counts were not consistent among patients. The number of malignant lymphoblasts in circulation did not correlate with the degree of bone marrow infiltration with cancer cells. In aggregate, these observations derived from a small number of cats suggest that ALL can present heterogeneously in a population of cats and that, overall, prognosis is generally poor, regardless of therapeutic intervention. Additional prospective studies are necessary to gain a deeper understanding of the biology and management of ALL in cats.

... TO YOUR PATIENTS

Key pearls to put into practice:

- 1** The absence of elevated circulating lymphoblasts does not exclude a diagnosis of ALL.
- 2** Diagnosis of ALL is best achieved through a combination of molecular techniques (eg, PCR for antigen receptor gene rearrangements, flow cytometry, immunohistochemistry).
- 3** The prognosis of ALL remains poor, regardless of instituted therapy, and retroviral infections with FeLV are often associated with ALL diagnosis in younger cats.

References

1. Fan TM. Lymphoma updates. *Vet Clin North Am Small Anim Pract.* 2003;33(3):455-471.
2. Cannon CM, Knudson C, Borgatti A. Clinical signs, treatment, and outcome in cats with myeloma-related disorder receiving systemic therapy. *J Am Anim Hosp Assoc.* 2015;51(4):239-248.
3. Campbell MW, Hess PR, Williams LE. Chronic lymphocytic leukaemia in the cat: 18 cases (2000-2010). *Vet Comp Oncol.* 2013;11(4):256-264.
4. Patel RT, Caceres A, French AF, McManus PM. Multiple myeloma in 16 cats: a retrospective study. *Vet Clin Pathol.* 2005;34(4):341-352.
5. Rout ED, Avery PR. Lymphoid neoplasia: correlations between morphology and flow cytometry. *Vet Clin North Am Small Anim Pract.* 2017;47(1):53-70.
6. Workman HC, Vernau W. Chronic lymphocytic leukemia in dogs and cats: the veterinary perspective. *Vet Clin North Am Small Anim Pract.* 2003;33(6):1379-1399, viii.
7. Davis LL, Hume KR, Stokol T. A retrospective review of acute myeloid leukaemia in 35 dogs diagnosed by a combination of morphologic findings, flow cytometric immunophenotyping and cytochemical staining results (2007-2015). *Vet Comp Oncol.* 2018;16(2):268-275.
8. Matus RE, Leifer CE, MacEwen EG. Acute lymphoblastic leukemia in the dog: a review of 30 cases. *J Am Vet Med Assoc.* 1983;183(8):859-862.

Research Note: Recovery After Congenital Portosystemic Shunt Attenuation Surgery

Predicting outcomes after congenital portosystemic shunt attenuation surgery in dogs can be difficult. Successful recovery depends on the ability of the liver and portal vasculature to regenerate and function normally. This study evaluated preoperative plasma albumin levels and intraoperative hepatic gene product mRNA expression in 73 dogs undergoing congenital portosystemic shunt surgery. Mean plasma albumin in recovered dogs was significantly higher than in dogs that died or were euthanized. Forty-three genes were differentially expressed in recovered vs nonrecovered dogs. Of these, *DHDH*, *ERLEC1*, and *LYSMD2* gene expression levels were most predictive of outcome. Validation of this model and development of less-invasive means for measuring predictive gene expression (eg, peripheral blood samples vs hepatic biopsy) would be needed to increase clinical applicability.

Source

Van den Bossche L, van Steenbeek FG, Weber MF. Genome-wide based model predicting recovery from portosystemic shunting after liver shunt attenuation in dogs. *J Vet Intern Med.* 2018;32(4):1343-1352.